208 related articles for article (PubMed ID: 28935469)
1. Risk of Guillain-Barré Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink.
Gee J; Sukumaran L; Weintraub E;
Vaccine; 2017 Oct; 35(43):5756-5758. PubMed ID: 28935469
[TBL] [Abstract][Full Text] [Related]
2. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England.
Andrews N; Stowe J; Miller E
Vaccine; 2017 Mar; 35(13):1729-1732. PubMed ID: 28245941
[TBL] [Abstract][Full Text] [Related]
3. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
[TBL] [Abstract][Full Text] [Related]
4. Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010.
Greene SK; Rett M; Weintraub ES; Li L; Yin R; Amato AA; Ho DT; Sheikh SI; Fireman BH; Daley MF; Belongia EA; Jacobsen SJ; Baxter R; Lieu TA; Kulldorff M; Vellozzi C; Lee GM
Am J Epidemiol; 2012 Jun; 175(11):1100-9. PubMed ID: 22582210
[TBL] [Abstract][Full Text] [Related]
5. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
Miller ER; McNeil MM; Moro PL; Duffy J; Su JR
Vaccine; 2020 Nov; 38(47):7458-7463. PubMed ID: 33039207
[TBL] [Abstract][Full Text] [Related]
6. Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.
Ojha RP; Jackson BE; Tota JE; Offutt-Powell TN; Singh KP; Bae S
Hum Vaccin Immunother; 2014; 10(1):232-7. PubMed ID: 24013368
[TBL] [Abstract][Full Text] [Related]
7. Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans.
Wise ME; Viray M; Sejvar JJ; Lewis P; Baughman AL; Connor W; Danila R; Giambrone GP; Hale C; Hogan BC; Meek JI; Murphree R; Oh JY; Reingold A; Tellman N; Conner SM; Singleton JA; Lu PJ; DeStefano F; Fridkin SK; Vellozzi C; Morgan OW
Am J Epidemiol; 2012 Jun; 175(11):1110-9. PubMed ID: 22582209
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
[TBL] [Abstract][Full Text] [Related]
9. Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010.
Polakowski LL; Sandhu SK; Martin DB; Ball R; Macurdy TE; Franks RL; Gibbs JM; Kropp GF; Avagyan A; Kelman JA; Worrall CM; Sun G; Kliman RE; Burwen DR
Am J Epidemiol; 2013 Sep; 178(6):962-73. PubMed ID: 23652165
[TBL] [Abstract][Full Text] [Related]
10. Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study.
Amend KL; Turnbull B; Zhou L; Marks MA; Velicer C; Saddier P; Seeger JD
Hum Vaccin Immunother; 2022 Nov; 18(5):2073750. PubMed ID: 35714277
[TBL] [Abstract][Full Text] [Related]
11. Papillomavirus vaccination and Guillain-Barre Syndrome among girls: A cohort study in Spain.
Martín-Merino E; Castillo-Cano B; Martín-Perez M; Llorente-García A; Montero-Corominas D
Vaccine; 2021 Jul; 39(31):4306-4313. PubMed ID: 34175126
[TBL] [Abstract][Full Text] [Related]
12. Lack of association of Guillain-Barré syndrome with vaccinations.
Baxter R; Bakshi N; Fireman B; Lewis E; Ray P; Vellozzi C; Klein NP
Clin Infect Dis; 2013 Jul; 57(2):197-204. PubMed ID: 23580737
[TBL] [Abstract][Full Text] [Related]
13. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.
Dodd CN; Romio SA; Black S; Vellozzi C; Andrews N; Sturkenboom M; Zuber P; Hua W; Bonhoeffer J; Buttery J; Crawford N; Deceuninck G; de Vries C; De Wals P; Gutierrez-Gimeno MV; Heijbel H; Hughes H; Hur K; Hviid A; Kelman J; Kilpi T; Chuang SK; Macartney K; Rett M; Lopez-Callada VR; Salmon D; Gimenez-Sanchez F; Sanz N; Silverman B; Storsaeter J; Thirugnanam U; van der Maas N; Yih K; Zhang T; Izurieta H;
Vaccine; 2013 Sep; 31(40):4448-58. PubMed ID: 23770307
[TBL] [Abstract][Full Text] [Related]
14. Adverse events following HPV vaccination: 11 years of surveillance in Australia.
Phillips A; Hickie M; Totterdell J; Brotherton J; Dey A; Hill R; Snelling T; Macartney K
Vaccine; 2020 Aug; 38(38):6038-6046. PubMed ID: 32709432
[TBL] [Abstract][Full Text] [Related]
15. Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011.
Greene SK; Rett MD; Vellozzi C; Li L; Kulldorff M; Marcy SM; Daley MF; Belongia EA; Baxter R; Fireman BH; Jackson ML; Omer SB; Nordin JD; Jin R; Weintraub ES; Vijayadeva V; Lee GM
PLoS One; 2013; 8(6):e67185. PubMed ID: 23840621
[TBL] [Abstract][Full Text] [Related]
16. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020.
Hu Y; Pan X; Shen L; Chen F; Wang Y; Liang H; Chen Y; Lv H
Hum Vaccin Immunother; 2021 Dec; 17(12):5447-5453. PubMed ID: 34613883
[TBL] [Abstract][Full Text] [Related]
17. Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018-2019 Season.
Perez-Vilar S; Hu M; Weintraub E; Arya D; Lufkin B; Myers T; Woo EJ; Lo AC; Chu S; Swarr M; Liao J; Wernecke M; MaCurdy T; Kelman J; Anderson S; Duffy J; Forshee RA
J Infect Dis; 2021 Feb; 223(3):416-425. PubMed ID: 33137184
[TBL] [Abstract][Full Text] [Related]
18. Guillain-Barré syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009.
Souayah N; Michas-Martin PA; Nasar A; Krivitskaya N; Yacoub HA; Khan H; Qureshi AI
Vaccine; 2011 Jan; 29(5):886-9. PubMed ID: 20869467
[TBL] [Abstract][Full Text] [Related]
19. Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine.
Deceuninck G; Sauvageau C; Gilca V; Boulianne N; De Serres G
Expert Rev Vaccines; 2018 Jan; 17(1):99-102. PubMed ID: 28972438
[TBL] [Abstract][Full Text] [Related]
20. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
